Meeting
2022 ASCO Annual Meeting
Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
Authors
Jillian Moran
Creatv MicroTech, Inc., Monmouth Junction, NJ
Jillian Moran , Daniel L Adams , Pablo Lopez Bravo , Jianzhong He , Yawei Qiao , Ting Xu , Zhongxing X. Liao , Kirby P Gardner , Cha-Mei Tang , Steven H. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8535)
DOI
10.1200/JCO.2022.40.16_suppl.8535
Abstract #
8535
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2021 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
First Author: Luis G. Paz-Ares
Poster
2020 ASCO Virtual Scientific Program
CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).
First Author: Sara M. Tolaney
First Author: Ana Oaknin